Adamo monobial-like drug Handa is ® in China

On December 26, 2020, Wanbang Pharma, a subsidiary of Shanghai Fosun Pharma (Group) Co., Ltd., officially announced that the Adamo single anti-injection (commodity name: Handayuan®) developed and produced by Fosun Pharmaceutical Biopharmaceutical Platform Fuhong Hanxuan was officially listed nationwide.
the drug has been approved by the National Drug Administration (NMPA), and adaptations include rheumatoid arthritis, severe spina bifidosis and psoriasis.
Handayuan (R) to the original study of adamo monoantigen as a reference drug, and with the original study of adamo monoantigen conducted a number of head-to-head matching studies, the results show that Handayuan (R) in terms of quality, safety and effectiveness and other aspects of the original drug is highly similar.
to further help patients manage their illnesses.
Adamu monoantigen is the world's first approved all-human source anti-tumor necrotic cause ɑ (TNF-ɑ) monoclonal antibody, which specifically binds to soluble human TNF-ɑ and blocks its interaction with cell surface TNF ligands p55 and p75, effectively blocking the inflammatory effects of TNF-ɑ. More than
clinical trials have confirmed that Adamo single anti-rheumatoid arthritis, strong straight spina bifida, psoriasis and other autoimmune diseases have shown significant efficacy, quickly replaced glucosticoids, non-steroidal anti-inflammatory drugs became the clinical first choice, access to North America, Europe, a number of guidelines unanimously recommended.
The executive director of the Chinese Physicians Association and president of the rheumatology immunologist branch, the 9th and 10th chairman of the Rheumatology Credit Union of the Chinese Medical Association, professor Zeng Xiaofeng, director of the rheumatology immunology department of Beijing Concord Hospital, said: "Strong spinal inflammation has the characteristics of high recurrence rate and high disability rate, and the lack of understanding of biological agents and unaffordable problems, is the main problem that plagues patients with standardized treatment."
(R) is highly similar to the original drug in terms of quality, safety and ability, and believes its launch is expected to lay a favorable foundation for standard and standardized treatment of patients.
Professor Zhang Jianzhong, Chairman of the 13th Committee of the Chinese Medical Association's Dermatological Society and Director of Dermatology Department of Peking University People's Hospital, said: "Biologics are becoming more and more widely used in the treatment of psoriasis, and clinically they need to be used rationally.
So far, among the listed Adamo monobial-like drugs, Handayuan (R) is the only Adamu monobial-like drug in China to carry out Phase III clinical research on patients with common psoriasis in China, and has accumulated more valuable clinical evidence and experience for the application of Adamo monoantigen in Chinese psoriasis patients.
" it is understood that Handayuan (R) pricing is also expected to become the most competitive Adamo monobial similar drugs.
the listing of Handayuan (R) provides new drug options for patients using Adamo monotherapy in China, and by reducing the cost of treatment, every autoimmune patient has the opportunity to receive standardized treatment.
The continuous development of biosynthetic drugs in China has provided patients with higher quality and more access to innovative therapeutic drugs and treatment options, while promoting the rational use of biosynthetic drugs in China through biosynthetic science education to help more patients achieve affordable treatment.
。